Abbott (ABT) Up 1.8% Since Last Earnings Report: Can It Continue?

Core Viewpoint - Abbott's shares have increased by approximately 1.8% since the last earnings report, underperforming the S&P 500, raising questions about the sustainability of this trend leading up to the next earnings release [1] Estimates Movement - Estimates for Abbott have trended upward over the past month, indicating a positive outlook [2] VGM Scores - Abbott has a subpar Growth Score of D, a Momentum Score of C, and a Value Score of C, resulting in an overall aggregate VGM Score of D, placing it in the middle 20% for investment strategy [3] Outlook - The magnitude of estimate revisions for Abbott has been net zero, and it holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Performance - Abbott is part of the Zacks Medical - Products industry, where competitor Neogen has seen a significant gain of 49.4% over the past month, despite reporting a year-over-year revenue decline of 3.4% [5] - Neogen's expected earnings for the current quarter are $0.10 per share, unchanged from the previous year, but the Zacks Consensus Estimate has decreased by 23.8% over the last 30 days, resulting in a Zacks Rank 4 (Sell) for Neogen [6]